SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

DHFR-IN-4

Cat. No.: HY-151159

CAS No.: 2820126-49-4

Molecular Formula: $C_{18}H_{21}N_5O_2S$

Molecular Weight: 371.46

Target: EGFR; Dihydrofolate reductase (DHFR)

Pathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (336.51 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6921 mL	13.4604 mL	26.9208 mL
	5 mM	0.5384 mL	2.6921 mL	5.3842 mL
	10 mM	0.2692 mL	1.3460 mL	2.6921 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with an IC_{50} value of 123 nM. DHFR-IN-4 also has inhibitory activity against EGFR and HER2 with IC_{50}s of 246 nM and 357 nM, respectively. DHFR-IN-4 has remarkable broad spectrum cytotoxic potency against cancer cells[1].

IC_{50} & Target

IC_{50}: 123 nM (DHFR), 246 nM (EGFR), 357 nM (HER2)[1]

In Vitro

DHFR-IN-4 (compound 42) (0-100 μM; 72 h) shows remarkable broad spectrum cytotoxic potency against HepG2, MCF-7, HCT-116, PC3 and HeLa[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line:	HepG2, MCF-7, HCT-116, PC3 and HeLa
Concentration:	0-100 μM

Incubation Time:	72 h
Result:	Exhibited antiproliferative activity against HepG2, MCF-7, HCT-116, PC3 and HeLa with IC_{50} s of 9.67±0.7 μM, 8.46±0.7 μM, 13.24±0.9 μM, 11.17±1.0 μM and 6.90±0.5 μM.

REFERENCES

[1]. Sabry MA, et al. New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity. Eur J Med Chem. 2022 Aug 10;241:114661.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA